Related Experiment Video

Updated: Mar 16, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K

MZF-1/Elk-1 interaction domain as therapeutic target for protein kinase Cα-based triple-negative breast cancer cells

Chia-Jen Lee1, Li-Sung Hsu2,3, Chia-Herng Yue4,5

  • 1Center for Molecular Medicine, China Medical University Hospital, Taichung 40402, Taiwan.

Oncotarget
|August 20, 2016
PubMed

Insights

Targeting the MZF-1/Elk-1 interaction blocks protein kinase C alpha (PKCα) in triple-negative breast cancer (TNBC). This novel strategy reduces cancer cell migration and tumorigenicity, offering a new therapeutic avenue for TNBC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Protein kinase C alpha (PKCα) expression is linked to poor survival in triple-negative breast cancer (TNBC).
  • Previous attempts to target PKCα are limited by off-target effects and an incomplete understanding of its upstream regulators.
  • Identifying novel therapeutic targets in TNBC is crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate the role of myeloid zinc finger 1 (MZF-1) and Ets-like protein-1 (Elk-1) in regulating PKCα expression in TNBC.
  • To elucidate the molecular mechanism by which MZF-1 and Elk-1 interact to modulate PKCα.
  • To evaluate the therapeutic potential of inhibiting the MZF-1/Elk-1 interaction in TNBC.

Main Methods:

  • Correlation analysis of MZF-1 and Elk-1 expression with PKCα in TNBC patient data.
  • In vitro studies using peptide fragments to block MZF-1/Elk-1 heterodimerization.
  • Assessment of DNA-binding activity of the MZF-1/Elk-1 complex to the PKCα promoter.
  • Functional assays measuring PKCα expression, cell migration, tumorigenicity, and epithelial-mesenchymal transition (EMT) in TNBC cells.

Main Results:

  • MZF-1 and Elk-1 expression positively correlates with PKCα levels in TNBC.
  • The acidic domain of MZF-1 and the heparin-binding domain of Elk-1 are essential for their heterodimeric interaction.
  • Blocking MZF-1/Elk-1 interaction with specific peptides significantly reduces PKCα promoter binding and subsequent gene expression.
  • Inhibition of the MZF-1/Elk-1 complex decreases TNBC cell migration, tumorigenicity, and EMT potential.
  • Re-expression of full-length PKCα reverses the inhibitory effects, confirming the MZF-1/Elk-1 complex as a key mediator.

Conclusions:

  • The MZF-1/Elk-1 heterodimer is a critical upstream regulator of PKCα in triple-negative breast cancer.
  • Targeting the MZF-1/Elk-1 interaction represents a promising therapeutic strategy for TNBC.
  • Inhibiting this interaction offers a more specific approach to downregulating PKCα compared to direct targeting.
Keywords:
Elk-1MZF-1PKCαtriple-negative breast cancer cells

More Related Videos

Mosaic Zebrafish Transgenesis for Functional Genomic Analysis of Candidate Cooperative Genes in Tumor Pathogenesis09:45

Mosaic Zebrafish Transgenesis for Functional Genomic Analysis of Candidate Cooperative Genes in Tumor Pathogenesis

Published on: March 31, 2015

11.8K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

6.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
88.3K